Pharmacophore-guided de novo drug design with diffusion bridge

• URL: http://arxiv.org/abs/2412.19812v2
• Date: Mon, 27 Jan 2025 05:43:48 GMT
• Title: Pharmacophore-guided de novo drug design with diffusion bridge
• Authors: Conghao Wang, Jagath C. Rajapakse,
• Abstract summary: We propose PharmacoBridge, a phamacophore-guided de novo design approach to generate drug candidates inducing desired bioactivity via diffusion bridge. Our method adapts the diffusion bridge to effectively convert pharmacophore arrangements in the spatial space into molecular structures.
• Score: 1.450261153230204
• License:
• Abstract: De novo design of bioactive drug molecules with potential to treat desired biological targets is a profound task in the drug discovery process. Existing approaches tend to leverage the pocket structure of the target protein to condition the molecule generation. However, even the pocket area of the target protein may contain redundant information since not all atoms in the pocket is responsible for the interaction with the ligand. In this work, we propose PharmacoBridge, a phamacophore-guided de novo design approach to generate drug candidates inducing desired bioactivity via diffusion bridge. Our method adapts the diffusion bridge to effectively convert pharmacophore arrangements in the spatial space into molecular structures under the manner of SE(3)-equivariant transformation, providing sophisticated control over optimal biochemical feature arrangements on the generated molecules. PharmacoBridge is demonstrated to generate hit candidates that exhibit high binding affinity with potential protein targets.

Related papers

• Aligning Target-Aware Molecule Diffusion Models with Exact Energy Optimization [147.7899503829411]
  AliDiff is a novel framework to align pretrained target diffusion models with preferred functional properties. It can generate molecules with state-of-the-art binding energies with up to -7.07 Avg. Vina Score.
  arXiv  Detail & Related papers  (2024-07-01T06:10:29Z)
• DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design [62.68420322996345]
  Existing structured-based drug design methods treat all ligand atoms equally. We propose a new diffusion model, DecompDiff, with decomposed priors over arms and scaffold. Our approach achieves state-of-the-art performance in generating high-affinity molecules.
  arXiv  Detail & Related papers  (2024-02-26T05:21:21Z)
• Learning Subpocket Prototypes for Generalizable Structure-based Drug Design [17.61987808099346]
  Deep generative models have achieved remarkable success in generating 3D molecules conditioned on the protein pocket. Most existing methods consider molecular generation for protein pockets independently. We propose a novel method DrugGPS for generalizable structure-based drug design.
  arXiv  Detail & Related papers  (2023-05-22T13:49:49Z)
• Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks [0.0]
  We propose an end-to-end generative system, DrugGEN, for the de novo design of drug candidate molecules. The system is trained using a large dataset of drug-like compounds and target-specific bioactive molecules. Using the open-access DrugGEN, it is possible to easily train models for other druggable proteins.
  arXiv  Detail & Related papers  (2023-02-15T18:59:27Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• PGMG: A Pharmacophore-Guided Deep Learning Approach for Bioactive Molecular Generation [5.168827506745199]
  We propose PGMG, a pharmacophore-guided deep learning approach for bioactivate molecule generation. We show that PGMG can generate molecules matching given pharmacophore models while maintaining a high level of validity, uniqueness, and novelty. Overall, the flexibility and effectiveness of PGMG make it a useful tool for accelerating the drug discovery process.
  arXiv  Detail & Related papers  (2022-07-02T12:31:17Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Molecular Design in Synthetically Accessible Chemical Space via Deep Reinforcement Learning [0.0]
  We argue that existing generative methods are limited in their ability to favourably shift the distributions of molecular properties during optimization. We propose a novel Reinforcement Learning framework for molecular design in which an agent learns to directly optimize through a space of synthetically-accessible drug-like molecules.
  arXiv  Detail & Related papers  (2020-04-29T16:29:28Z)
• Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning [75.95376096628135]
  We propose a novel forward synthesis framework powered by reinforcement learning (RL) for de novo drug design. In this setup, the agent learns to navigate through the immense synthetically accessible chemical space. We describe how the end-to-end training in this study represents an important paradigm in radically expanding the synthesizable chemical space.
  arXiv  Detail & Related papers  (2020-04-26T21:40:03Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.